Literature DB >> 32453918

Uncrossable and undilatable lesions-A practical approach to optimizing outcomes in PCI.

Conor McQuillan1, Matthew W P Jackson1, Emmanouil S Brilakis2, Mohaned Egred1,3.   

Abstract

Uncrossable lesions are those that cannot be crossed with a balloon after successful guidewire crossing. These lesions are challenging and are commonly encountered in tortuous and calcified arteries as well as chronic total occlusions. They are the second most common barrier to successful PCI in CTO intervention after inability to cross the CTO segment with a guidewire. Procedures involving balloon uncrossable lesions during routine and CTO PCI utilise longer procedural times, radiation dose and contrast volumes with a lower likelihood of procedural success. In this article, we describe a pragmatic approach of managing balloon uncrossable lesions utilising the most contemporary equipment available in an algorithmic fashion beginning with simple, cost effective techniques right up to complex strategies for advanced operators. In addition, some of these lesions, even when crossed by any technique, they may remain difficult to dilate and prepare for stent insertion. We describe an approach of how to manage these undilatable lesions.
© 2020 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.

Keywords:  CHIP PCI; Resistant lesions; atherectomy, directional/rotational; complex PCI; coronary artery disease; laser; percutaneous coronary intervention

Year:  2020        PMID: 32453918     DOI: 10.1002/ccd.29001

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  1 in total

1.  Rota-Lithotripsy-A Novel Bail-Out Strategy for Calcified Coronary Lesions in Acute Coronary Syndrome. The First-in-Man Experience.

Authors:  Adrian Włodarczak; Piotr Rola; Mateusz Barycki; Jan Jakub Kulczycki; Marek Szudrowicz; Maciej Lesiak; Adrian Doroszko
Journal:  J Clin Med       Date:  2021-04-26       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.